Cryo-Cell International, Inc. Quarterly report pursuant to Section 13 or 15(d)

Notes Payable (Tables)

9 Months Ended

Aug. 31, 2022

As of August 31, 2022 and November 30, 2021, the note payable obligation was as follows:


	August 31, 2022			November 30, 2021
Note payable - TCB	$	—		$	1,908,433
Note payable - Susser		8,960,000
Unamortized debt issuance costs - TCB		—			(10,368	)
Unamortized debt issuance costs - Susser		(196,501	)		—
Net note payable	$	8,763,499		$	1,898,065
Current portion of note payable	$	154,252		$	1,898,065
Long-term note payable, net of debt issuance costs		8,609,247			—
Total	$	8,763,499		$	1,898,065

Interest expense on the note payable for the three and nine months ended August 31, 2022 and 2021 was as follows:


	For the three months ended		For the nine months ended
	August 31, 2022		August 31, 2022
Interest expense on notes payable - TCB	$	370	$	18,485
Interest expense on notes payable - Susser		89,585		89,585
Debt issuance costs - TCB		592		10,368
Total interest expense	$	90,547	$	118,438


	For the three months ended		For the nine months ended
	August 31, 2021		August 31, 2021
Interest expense on notes payable - TCB	$	25,862	$	99,294
Debt issuance costs - TCB		12,390		47,462
Total interest expense	$	38,252	$	146,756